Buprenorphine for Probationers and Parolees: Bridging the Gap Into Treatment

PHASE3RecruitingINTERVENTIONAL
Enrollment

320

Participants

Timeline

Start Date

July 1, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions
Opioid Use
Interventions
DRUG

Buprenorphine/Naloxone

Participants will begin buprenorphine pharmacotherapy using the MedicaSafe buprenorphine dispensing device immediately after an on-site intake at a community supervision office and continue such treatment until they are transitioned to community buprenorphine treatment

OTHER

Treatment as usual

Participants will receive a referral to buprenorphine treatment in the community

Trial Locations (1)

21202

RECRUITING

Division of Parole & Probation, Baltimore

All Listed Sponsors
lead

Friends Research Institute, Inc.

OTHER